CompletedPhase 2NCT00483496
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Studying Solar urticaria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Orfagen
- Principal Investigator
- Patrick Dupuy, DrOrfagen
- Intervention
- Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)(drug)
- Enrollment
- 16 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2008
Study locations (3)
- Henry Ford Medical Center, Detroit, Michigan, United States
- St Luke's Roosevelt Hospital Center, New York, New York, United States
- Ninewells Hospital, Dundee, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00483496 on ClinicalTrials.gov